EACS2023: 814 Real world use of long-acting cabotegravir and rilpivirine in a HIV centre in Hong Kong M.C.J. Chan , S.H.T. Chik , S.S. Lamb , Y.C.C. Choi , W.T.A. Lau , C.S.E. Leung , P.Y.L. To , P.L.D. Lau , T.Y.O. Tsang Hospital Authority Infectious Disease Centre, Hong Kong, Hong Kong, SAR of China General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: The new modality of long-acting (LA) antiretroviral therapy (ART) regimen cabotegravir and rilpivirine (CAB+RPV) was introduced in Hong Kong since June 2022. We conducted a retrospective cohort in reviewing the patient characteristics and clinical effectiveness of CAB+RPV among Chinese patients in Hong Kong. Method: Medical records were retrieved for all ART-experienced patients receiving CAB+RPV LA regimens in HIV clinic, Princess Margaret Hospital, Hong Kong. Retrospective data was collected between 1 July 2022 and 30 June 2023. Baseline clinical characteristics at the time of drug switch, subsequent viral suppression and drug compliance were reviewed. Results: A total of 18 patients prescribed CAB+RPV were recruited. All were ART-experienced, with 67% had undetectable VL (<12.1 copies/ml) and 33% had detectable but not quantifiable VL (<30 copies/ml). All patients were Chinese, with 17 male and 1 female and the median age was 37. At the time of drug switch, the median BMI was 23.5 and median CD4 count was 543 cells/mm . In this cohort, the median years of acquiring HIV infection was 7 and the most common reason for drug switch was alternative treatment modality to daily pills. For ART before switch, 83% were on 3-drug while 17% were on 2-drug regimen. 88% were on InSTIs-based and 12% were on NNRTI-based ART. For those with VL available after drug switch, the latest VL was <12.1 copies/ml in 71% and <30 copies/ml in 29%. At study end, all patients remained on CAB+RPV LA with a median follow-up of 5 months. Conclusions: In this retrospective real world cohort of HIV-infected Chinese individuals who received CAB+RPV LA injections in Hong Kong, good drug compliance and sustained VL suppression were observed in the first year of treatment. Patients with relatively long history of HIV infection may opt for injectables as an alternative treatment. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 1 1 1 1 1 1 3 161
RkJQdWJsaXNoZXIy Mzc2ODc=